Stock Update (NYSE:ACT): Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin

[PR Newswire] – DUBLIN and BOSTON, Oct. 22, 2014 /PRNewswire/ — Actavis plc (ACT), a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that Actavis has been granted an . . . → Read More: Stock Update (NYSE:ACT): Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin Similar Articles: Market Update (NYSE:ACT): Actavis to Acquire Durata Therapeutics, Inc. Stock Update: Actavis plc (NYSE:ACT) – Actavis Confirms Generic Butrans® Patent Challenge Company Update (NYSE:ACT): Actavis to Present at Morgan Stanley Global Healthcare Conference 2014